國藥現代(600420.SH)半年度淨利升30.48%至4.26億元
格隆匯7月14日丨國藥現代(600420.SH)披露半年度業績快報，實現營業總收入約76.32億元，同比增長22.86%；實現利潤總額約6.39億元，同比增長24.98%；實現歸屬於上市公司股東的淨利潤約4.26億元，同比增長30.48%。
經營業績和財務狀況情況説明：
2021年上半年，公司直面複雜多變的市場環境，以“十四五”發展規劃為統領，穩步有序推進戰略規劃計劃體系之2021年度工作計劃的有效落地，充分把握市場機遇，進一步推動產業鏈一體化協同，持續深化提質增效，公司經營穩步增長。報吿期內，公司實現營業收入763,213.67萬元，較上年同期增長22.86%；實現歸屬於上市公司股東的淨利潤42,613.51萬元，較上年同期增長30.48%；實現歸屬於上市公司股東的扣除非經常性損益的淨利潤41,095.97萬元，較上年同期增長52.69%。
本期公司收入增長主要原因為：一方面公司主要醫藥中間體和部分重點原料藥產品的市場價格企穩回升，銷售收入佔比保持同比上升趨勢；另一方面，因國內疫情得到有效控制使得製劑產品市場需求較上年同期有所恢復，在銷量的拉動下，心腦血管、抗感染、維生素類與礦物質類以及消化系統等治療領域產品同比保持良好增長。
隨着公司中間體及原料藥、製劑產品兩大業態銷售規模同比增長，加之降本控費、精益化管理等各項提質增效措施的持續貫徹落實，帶動公司營業利潤同比增長31.10%，進而帶動了公司本期歸屬於上市公司股東的淨利潤、基本每股收益、加權平均淨資產收益率的上升；同時，由於本期收到的政府補助及處置資產利得較去年同期有所減少，使得本期歸屬於上市公司股東的扣除非經常性損益的淨利潤增幅明顯高於公司本期歸屬於上市公司股東的淨利潤增幅。
公司其他綜合收益為按照持股比例確認的聯營企業其他綜合收益。本期同比下降46.92%主要系聯營企業其他綜合收益較去年同期減少所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
